Back

A multicenter analysis of atrial fibrillation burden reduction with antiarrhythmic drugs in patients with cardiac implantable electronic devices

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation Rhythm Control, Antiarrhythmic Drugs ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Sarah Schwartz

Columbia University Irving Medical Centre, New York (United States of America)

6 More presentations in this session

Presentation thumbnail
Use of class ic antiarrhythmic drugs in atrial fibrillation with structural heart disease: a nationwide cohort study
Assistant Professor J. Jeong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomised controlled trials
Doctor M. Casuso Alvarez (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Improving management of patients with atrial fibrillation in the emergency department based on an aggressive rhythm control strategy. The HEROMEDICUS study.
Doctor N. Argyriou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Impact of statin and ezetimibe for the prevention of stroke in patients with atrial fibrillation
Associate Professor K. Lee (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
The contemporary guideline-directed medical therapy (GDMT) for heart failure is associated with a reduced incidence of new-onset atrial fibrillation in the elderly patients
Doctor Y. Mukai (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Clinical implications of atrial fibrillation recurrence vs. burden following catheter ablation: outcome data from 3 contemporary clinical trials using an insertable cardiac monitor
thumbnail
Congress Presentation
Atrial fibrillation burden should be the primary outcome in rhythm control trials: pro
thumbnail
Congress Presentation
Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources